The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells - PubMed (original) (raw)

. 1991 Aug;129(2):896-900.

doi: 10.1210/endo-129-2-896.

Affiliations

• PMID: 1855480
• DOI: 10.1210/endo-129-2-896

The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells

N Ferrara et al. Endocrinology. 1991 Aug.

Abstract

Intact 23 kilodalton (kDa), rat PRL is enzymatically cleaved in many target tissues to a 16 kDa (16K PRL) and an 8 kDa fragment. After reduction of an internal disulfide bond the fragments are released. 16K PRL was shown to be a potent mitogen on mammary epithelial cells via PRL receptors. Since estradiol-induced prolactinomas develop a new blood supply we tested the action of intact PRL and 16K PRL on growth of new vessels (angiogenesis). The angiogenic action of intact PRL and 16K PRL was tested in cultured bovine brain and adrenal cortex endothelial cells. Basal (b) or b-fibroblast growth factor (FGF) stimulated growth was estimated by counting cells or measuring the level of incorporation of 3H-thymidine into DNA. Paradoxically, 16K PRL inhibited the basal and FGF-stimulated growth of cultured endothelial cells in a dose-dependent fashion. Intact PRL or the cleaved but not reduced PRL were inactive even at a 100-fold higher concentration. When reformation of disulfide bonds was inhibited by carbamidomethylation of 16K PRL the preparations were more potent. 16K PRL had no effect on the mitogenic action of bFGF on baby hamster kidney cells which are known to have FGF receptors. These data demonstrate that in vitro 16K PRL is a potent and specific angiolytic factor, i.e. it inhibits angiogenesis. Furthermore, the action of 16K PRL does not appear to be via the known PRL or FGF receptors. Since angiogenesis is an essential component of tumor growth 16K PRL has potential as a therapeutic agent for the treatment of cancer.

PubMed Disclaimer

Similar articles

• The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
  Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. Clapp C, et al. Endocrinology. 1993 Sep;133(3):1292-9. doi: 10.1210/endo.133.3.7689950. Endocrinology. 1993. PMID: 7689950
• A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.
  Clapp C, Weiner RI. Clapp C, et al. Endocrinology. 1992 Mar;130(3):1380-6. doi: 10.1210/endo.130.3.1311239. Endocrinology. 1992. PMID: 1311239
• 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.
  Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, Barajas-Espinosa A, Diaz-Muñoz M, Rubio R, Lin SH, Martinez de la Escalera G, Clapp C. Gonzalez C, et al. Endocrinology. 2004 Dec;145(12):5714-22. doi: 10.1210/en.2004-0647. Epub 2004 Sep 9. Endocrinology. 2004. PMID: 15358675
• Regulation of blood vessels by prolactin and vasoinhibins.
  Clapp C, Thebault S, Macotela Y, Moreno-Carranza B, Triebel J, Martínez de la Escalera G. Clapp C, et al. Adv Exp Med Biol. 2015;846:83-95. doi: 10.1007/978-3-319-12114-7_4. Adv Exp Med Biol. 2015. PMID: 25472535 Review.
• Should prolactin be reconsidered as a therapeutic target in human breast cancer?
  Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA. Goffin V, et al. Mol Cell Endocrinol. 1999 May 25;151(1-2):79-87. doi: 10.1016/s0303-7207(99)00023-4. Mol Cell Endocrinol. 1999. PMID: 10411322 Review.

Cited by

• From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.
  Triebel J, Robles-Osorio ML, Garcia-Franco R, Martínez de la Escalera G, Clapp C, Bertsch T. Triebel J, et al. Front Endocrinol (Lausanne). 2017 Dec 11;8:342. doi: 10.3389/fendo.2017.00342. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 29321761 Free PMC article. Review.
• Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis.
  Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, Adamo L, Lau ES, Al'Aref SJ, Asnani A, Sharma G, Mehta JL. Kumar A, et al. Curr Probl Cardiol. 2023 Feb;48(2):101461. doi: 10.1016/j.cpcardiol.2022.101461. Epub 2022 Oct 17. Curr Probl Cardiol. 2023. PMID: 36261102 Free PMC article. Review.
• The role of angiogenesis in rheumatoid arthritis: recent developments.
  Koch AE. Koch AE. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i65-71. doi: 10.1136/ard.59.suppl_1.i65. Ann Rheum Dis. 2000. PMID: 11053092 Free PMC article. Review. No abstract available.
• Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues.
  Robles JP, Zamora M, Velasco-Bolom JL, Tovar M, Garduño-Juárez R, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. Robles JP, et al. Sci Rep. 2018 Nov 20;8(1):17111. doi: 10.1038/s41598-018-35383-7. Sci Rep. 2018. PMID: 30459448 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database